Biotinylation of Erythrocytes Prepares to Allow Circulation-Stable Immunoerythrocytes Capable of Recognizing the Antigen

  • Juan C. Murciano
  • Vladimir R. Muzykantov
  • Angel Herráez


Erythrocytes (RBC) have been studied as carriers of drugs for several years3. Their viability, physiologic characteristics and the availability of different procedures to incorporate substances into them support their utilization10. However, targeting is one of the major problems to solve in all these related therapies. Attachment of antibodies to the RBC surface has been pursued before2. This attachment may provide a way to target these carriers to the specific zone where the disease is, and also can serve as a means to eliminate hazardous antigens from the bloodstream. Biotin/streptavidin (b/SAv) complex is one of the systems to attach antibodies or other substances, such as enzymes, to the RBC surface5,9. Although there are several works which have proposed the development of immunoerythrocytes, little is known about their ability to recognize the antigen after their circulation in the animal model. Looking for these topics, in this work we investigate the attachment of biotinylated antibody (b-Ab) to biotinylated RBC by means of bridging SAv molecules. We show that moderate biotinylation of the RBC allows to attach 3 to 5 ×104 molecules of b-Ab and creates immunoerythrocytes that are stable in circulation. The b-Ab remains attached to the RBC while they are circulating. Furthermore, the immunoerythrocytes entirely retain the ability to recognize the antigen.


Left Axis Ester Lead Antigen Delivery System Antigen Binding Capacity Biotin Residue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    E.A. Bayer and M. Wilchek, Protein biotinylation. Methods Enzymol. 184:138 (1990).PubMedCrossRefGoogle Scholar
  2. 2.
    L. Chiarantini, R.E. Droleskey, M. Magnani, and J.R. DeLoach, In vitro targeting of erythrocytes to cytotoxic T-cells by coupling of Thy-1.2 monoclonal antibody. Biotechnol. Appl. Biochem. 15:171 (1992).PubMedGoogle Scholar
  3. 3.
    K. Kinosita and T.Y. Tsong, Voltage-induced pore formation and hemolysis of human erythrocytes. Nature 272:258(1978).PubMedCrossRefGoogle Scholar
  4. 4.
    D.L. Kooyman, G.W. Byrne, S. McClellan, D. Nielsen, M. Tone, H. Waldmann, T.M. Coffman, K.R. McCurry, J.L. Platt, and J.S. Logan, In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 269:89 (1995).PubMedCrossRefGoogle Scholar
  5. 5.
    M. Magnani, L. Chiarantini, E. Vittoria, U. Mancini, L. Rossi, and A. Fazi, Red blood cells as an antigen delivery system. Biotechnol. Appl. Biochem. 16:188 (1992).PubMedGoogle Scholar
  6. 6.
    V.R. Muzykantov and J.C. Murciano, Attachment of antibody to biotinylated red blood cells: Immunoerythrocytes display high affinity to immobilized antigen and normal biodistribution in rats. Biotechnol. Appl. Biochem. 24:41 (1996).PubMedGoogle Scholar
  7. 7.
    V.R. Muzykantov, J.C. Murciano, R.P. Taylor, E.N. Atochina, and A. Herráez, Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin. Anal. Biochem. 241:109(1996).PubMedCrossRefGoogle Scholar
  8. 8.
    V.R. Muzykantov, N. Seregina, and M. Smirnov, Fast lysis by complement and uptake by liver of avidincarrying biotinylated erythrocytes. Int. J. Artif. Organs 15:622 (1992).PubMedGoogle Scholar
  9. 9.
    V.R. Muzykantov and R.P. Taylor, Attachment of biotinylated antibody to red blood cells: Antigen-binding capacity of immunoerythrocytes and their susceptibility to lysis by complement. Anal. Biochem. 223:142 (1994).PubMedCrossRefGoogle Scholar
  10. 10.
    C. Ropars, B.P. Teisseire, M.C. Villereal, C. Bailleul, M. Chassaigne, and C. Nicolau, Engineered erythrocytes with high peripheral release of oxygen. In: “Biotechnology in Clinical Medicine” A. Albertini et al., eds. Raven Press, Ltd., New York (1987).Google Scholar
  11. 11.
    A.B. Zaltzman, K. van der Berg, V.R. Muzykantov, and B.P. Morgan, Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulator CD59. Biochem. J. 307:651 (1995).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Juan C. Murciano
    • 1
  • Vladimir R. Muzykantov
    • 2
  • Angel Herráez
    • 1
  1. 1.Department of Biochemistry and Molecular BiologyUniversity of Alcalá de HenaresSpain
  2. 2.Institute for Environmental MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations